ABBV

Company financials

AbbVie

Health Care Biotechnology North Chicago, Illinois Last filing Feb 20, 2026 · FY2025

                    Revenue
                    FY2025
                
$61.2B
                    3y CAGR +1.8%
                    
                    P29
                    
                    n/a
                    
                    Net income
                    FY2025
                
$4.2B
                    Net margin +6.9%
                    
                    P25
                    
                    n/a
                    
                    Total assets
                    FY2025
                
$134.0B
                    ROA +3.2%
                    
                    P25
                    
                    n/a
                    
                    Operating cash flow
                    FY2025
                
$19.0B
                    FCF margin +29.1%
                    
                    P96
                    
                    n/a

15 yrs · FY2011–FY2025 8 filed · 1 derived · 0 blank

1Y 3Y 5Y 10Y

Dollars % of revenue % of assets YoY % CAGR

Each cell as a share of that year’s revenue.

Balance Sheet

Assets, liabilities, and equity

26 accounts · 1 year

Total assets $134.0B

Total liabilities ~$137.2B

Shareholders equity $-3.3B

Account	2025	Trend
Assets
Cash and Cash Equivalents	8.5%
Short Term Investments	0.0%
Accounts Receivable	20.6%
Inventory	8.1%
Prepaid Expenses	10.2%
Total Current Assets	47.5%
Property,Plant and Equipment	9.2%
Goodwill	58.3%
Intangible Assets	86.1%
Long Term Investments	0.4%
Other Noncurrent Assets	17.5%
Total Assets	219.0%
Liabilities
Accounts Payable	56.8%
Current Portion of Long Term Debt	14.0%
Total Current Liabilities	70.8%
Long Term Debt	96.4%
Deferred Tax Liabilities	3.9%
Other Noncurrent Liabilities	53.3%
Equity
Common Stock	0.0%
Additional Paid In Capital	36.8%
Retained Earnings	-25.3%
Treasury Stock	15.0%
Accumulated Other Comprehensive Income	-1.9%
Total Stockholders Equity	-5.3%
Noncontrolling Interest	0.1%
Total Liabilitiesand Equity	219.0%

Income Statement

Revenue, expense, and profitability

16 accounts · 1 year

Revenue $61.2B

Operating income $15.1B

Net income $4.2B

Account	2025	Trend
IncomeStatement
Revenues Total Revenue	100.0%
Expenses Cost of Revenue	29.8%
Expenses Research and Development	23.1%
Expenses Selling,General and Administrative	22.9%
Expenses Other Operating Expenses	-0.4%
Other Income Expense Operating Income	24.6%
Other Income Expense Interest Expense	4.3%
Other Income Expense Other Income/expense	-9.6%
Other Income Expense Income Before Tax	10.8%
Income Tax Income Tax Expense	3.9%
net Income Other Items Below Tax	-0.0%
net Income net Income	6.9%
net Income Comprehensive Income	8.2%
Earnings Per Share Basic Eps	0.0%
Earnings Per Share Diluted Eps	0.0%
Earnings Per Share Weighted Average Shares Diluted	2.9%

Cash Flow Statement

Operating, investing, and financing flows

22 accounts · 1 year

Operating cash flow $19.0B

Investing cash flow $-6.6B

Financing cash flow $-12.7B

Account	2025	Trend
CashFlow
Operating Activities net Income	6.9%
Operating Activities Depreciation and Amortization	13.3%
Operating Activities Stock Based Compensation	1.6%
Operating Activities Deferred Income Taxes	-0.8%
Operating Activities Changes In Operating Assets and Liabilities	-3.9%
Operating Activities Other Non Cash Items	14.0%
Operating Activities net Cash From Operating Activities	31.1%
Investing Activities Capital Expenditures	-2.0%
Investing Activities Business Acquisitions	-0.3%
Investing Activities Purchases of Investments	-8.6%
Investing Activities Proceeds From Sale of Investments	0.1%
Investing Activities Other Investing Activities	-0.0%
Investing Activities net Cash From Investing Activities	-10.9%
Financing Activities Proceeds From Debt	14.4%
Financing Activities Repayment of Debt	-15.7%
Financing Activities Repurchase of Common Stock	-1.6%
Financing Activities Dividends Paid	-19.1%
Financing Activities Proceeds From Stock Issuance	0.3%
Financing Activities Other Financing Activities	0.9%
Financing Activities net Cash From Financing Activities	-20.8%
Cash Reconciliation Effect of Exchange Rate On Cash	0.1%
Cash Reconciliation net Change In Cash	-0.5%

Key Ratios

Margins, returns, liquidity, leverage, efficiency

Computed at import · 1 year

Ratio	2025
Profitability
Gross margin	+70.2%
Operating margin	+24.6%
Net margin	+6.9%
FCF margin	+29.1%
Growth
Revenue CAGR (3y)	+1.8%
Returns
ROE	-129.2%
ROA	+3.2%
ROIC	+16.4%
Liquidity
Current ratio	0.67x
Quick ratio	0.41x
Leverage
D/E	-41.97x
Interest coverage	5.74x
Efficiency
Asset turnover	0.46x
Cash conversion cycle	-522d

Valuation

Price against fundamentals

ABBV $218 · 2025-09-12 · 414d old · FY2025

Market cap $387.1B

P/E 91.60x

P/S 6.33x

P/B —

EV $449.4B

EV/EBITDA —

FCF yield +4.6%

Dividend yield +3.0%

Notes

Your annotations

Not watched

AbbVie

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Recent price history